## Ludmila V Danilova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8528152/publications.pdf

Version: 2024-02-01

60 papers 26,890 citations

35 h-index 59 g-index

67 all docs

67 docs citations

times ranked

67

39364 citing authors

#	Article	IF	CITATIONS
1	DNA-methylation for the detection and distinction of 19 human malignancies. Epigenetics, 2022, 17, 191-201.	2.7	7
2	Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 60, 103714.	2.0	10
3	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. ELife, 2021, 10, .	6.0	12
4	Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biology, 2021, 22, 154.	8.8	30
5	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
6	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer, 2021, 2, 891-903.	13.2	147
7	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research, 2021, 9, 1262-1269.	3.4	8
8	Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. Genome Medicine, 2021, 13, 129.	8.2	17
9	Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell, 2021, 184, 5031-5052.e26.	28.9	236
10	Systemic inhibition of PTPN22 augments anticancer immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	24
11	PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. Epigenetics, 2020, 15, 604-617.	2.7	15
12	Revisiting the tumorigenesis timeline with a data-driven generative model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 857-864.	7.1	44
13	Extracellular Vesicles Released by Tumor Endothelial Cells Spread Immunosuppressive and Transforming Signals Through Various Recipient Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 698.	3.7	18
14	Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy. Cancer Biology and Therapy, 2020, 21, 560-569.	3.4	17
15	Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Epigenetics, 2020, 15, 959-971.	2.7	17
16	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3578-3588.	7.0	76
17	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma., 2020, 8, e000394.		39
18	Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes. JCI Insight, 2020, 5, .	5.0	17

#	Article	IF	Citations
19	Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. Npj Systems Biology and Applications, 2019, 5, 29.	3.0	17
20	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	7.1	431
21	Differentially Methylated Super-Enhancers Regulate Target Gene Expression in Human Cancer. Scientific Reports, 2019, 9, 15034.	3.3	9
22	Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 2860-2873.	7.0	68
23	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research, 2019, 7, 886-895.	3.4	171
24	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1., 2019, 7, 40.		42
25	Diagnostic utility of telomere length testing in a hospital-based setting. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2358-E2365.	7.1	165
26	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
27	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
28	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
29	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
30	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
31	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
32	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
33	MVisAGe Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors. Cancer Research, 2018, 78, 3375-3385.	0.9	5
34	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
35	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
36	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, $2018,10,10$	12.4	178

#	Article	IF	Citations
37	Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Briefings in Functional Genomics, 2018, 17, 49-63.	2.7	111
38	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab., 2018, 6, 99.		129
39	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422
40	Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Medicine, 2018, 10, 37.	8.2	25
41	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
42	Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Translational Research, 2018, 202, 109-119.	5.0	15
43	Discovery and development of differentially methylated regions in human papillomavirusâ€related oropharyngeal squamous cell carcinoma. International Journal of Cancer, 2018, 143, 2425-2436.	5.1	35
44	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research, 2018, 6, 888-899.	3.4	118
45	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
46	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics, 2017, 12, 540-550.	2.7	43
47	Integrated Analysis of Whole-Genome ChIP-Seq and RNA-Seq Data of Primary Head and Neck Tumor Samples Associates HPV Integration Sites with Open Chromatin Marks. Cancer Research, 2017, 77, 6538-6550.	0.9	50
48	A Novel Functional Splice Variant of <i>AKT3</i> Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. Cancer Research, 2017, 77, 5248-5258.	0.9	41
49	DNA methylation regulates TMEM16A/ANO1 expression through multiple CpG islands in head and neck squamous cell carcinoma. Scientific Reports, 2017, 7, 15173.	3.3	20
50	Integrative computational analysis of transcriptional and epigenetic alterations implicates <i>DTX1</i> as a putative tumor suppressor gene in HNSCC. Oncotarget, 2017, 8, 15349-15363.	1.8	16
51	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
52	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	8.8	746
53	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	7.1	145
54	Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods, 2016, 13, 310-318.	19.0	209

#	Article	IF	CITATIONS
55	A multi-omic analysis of human naìve CD4+ T cells. BMC Systems Biology, 2015, 9, 75.	3.0	43
56	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
57	Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e93102.	2.5	87
58	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
59	Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15544-15549.	7.1	317
60	Preferential Activation of the Hedgehog Pathway by Epigenetic Modulations in HPV Negative HNSCC Identified with Meta-Pathway Analysis. PLoS ONE, 2013, 8, e78127.	2.5	39